Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Univariate and multivariate analyses of predictive factors for successful maintenance with steroid-sparing immunosuppressant monotherapy in patients with anti-HMGCR myopathy (N = 55)

From: Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

 Maintenance of remission with SSI monotherapyUnivariateMultivariate
Yes (n = 30), n (%) or Median (range)No (n = 25), n (%) or Median (range)OR (95% CI), P valueOR (95% CI), P value
Age at treatment initiation, Median (range) years68.2 (48.5–86.1)66.9 (44.0–83.1)1.02 (0.97 to 1.08), P = 0.516
Male sex, n (%)17 (57)13 (52)1.21 (0.41 to 3.54), P = 0.729
Normal strength at treatment initiation, n (%)5 (17)4 (16)1.05 (0.25 to 4.72), P = 0.947
CK at treatment initiation, Median (range) UI/L4959 (554–23,000)5083 (1533–14,098)1.00 (1.00 to 1.00), P = 0.582
Dysphagia, subjective, n (%)9 (30)7 (28)1.10 (0.34 to 3.65), P = 0.871
Dysphagia, objective, n (%)1 (3)4 (16)0.18 (0.01 to 1.33), P = 0.139
Delay between first increased serum CK and treatment initiation, Median (range) months2.0 (0–24.9)11.0 (0–95.0)0.94 (0.88 to 0.98), P = 0.0250.92 (0.85 to 0.97), P = 0.015
Use of corticosteroids in induction, n (%)23 (77)18 (72)1.28 (0.37 to 4.39), P = 0.693
Use of IVIG in induction, n (%)10 (33)19 (76)0.16 (0.04 to 0.50), P = 0.0020.08 (0.01 to 0.32), P = 0.001
  1. SSI steroid-sparing immunosuppressant